EOLS - Evolus, Inc. News

Discover

EOLS

Evolus, Inc.

8.15

2 x 7.39

1 x 8.18

bid

ask

0.13

1.68%

5 @ 04:00 PM

8.14 -0.01 (0.18%)

Ytd	22.63%
1y	27.42%

8.03

day range

8.26

3.94

52 week range

8.34

Open	8.05	Prev Close	8.02	Low	8.03	High	8.26	Mkt Cap	537.05M
Vol	648.71K	Avg Vol	848.81K	EPS	-0.32	P/E	-25.82	Forward P/E	54.20
Beta	1.31	Short Ratio	7.38	Inst. Own	80.22%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-04	50-d Avg	6.62	200-d Avg	5.91	1yr Est	23.43

EOLS News

defenseworld.net

Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

Assenagon Asset Management S.A. lifted its holdings in Evolus, Inc. (NASDAQ: EOLS) by 51.8% in the u

zacks.com

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in E

seekingalpha.com

Evolus: The Injectable Platform Is Becoming The Real Moat

Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and

seekingalpha.com

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

zacks.com

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus, Inc. (EOLS) reported break-even quarterly earnings per share versus the Zacks Consensus Esti

marketbeat.com

Evolus Q2 Earnings Call Highlights

Evolus NASDAQ: EOLS reported second-quarter revenue growth of 21% and raised the lower end of its fu

businesswire.com

Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of P

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty com

gurufocus.com

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, an

[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a global performance beauty company with a focus on buildi

businesswire.com

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, an

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty com

businesswire.com

Evolus to Report Second Quarter Financial Results on August 5, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company wi

businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company wi

businesswire.com

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty com

businesswire.com

Evolus to Participate in The Jefferies Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company wi

businesswire.com

Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty com

seekingalpha.com

Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript

zacks.com

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Esti

businesswire.com

Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty com

benzinga.com

Earnings Scheduled For May 4, 2026

defenseworld.net

Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference

Evolus (NASDAQ: EOLS) executives told investors at Needham and Company's 25th Annual Healthcare Conf

businesswire.com

Evolus to Report First Quarter Financial Results on May 4, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company wi

defenseworld.net

JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS

JPMorgan Chase and Co. decreased its holdings in Evolus, Inc. (NASDAQ: EOLS) by 35.5% in the undefin

benzinga.com

Earnings Scheduled For March 3, 2026

benzinga.com

Earnings Scheduled For November 5, 2025

benzinga.com

Earnings Scheduled For August 5, 2025

benzinga.com

Earnings Scheduled For May 7, 2025

benzinga.com

Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Pre

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market tr

benzinga.com

Stocks That Hit 52-Week Lows On Monday

benzinga.com

Stocks That Hit 52-Week Lows On Thursday